Latest Bcl-2 Stories
DUBLIN, April 14, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/c2rl8f/oncogene) has announced the addition of the "Oncogene Inhibitors
- First Patient Dosed in the "Wolverine" Phase II Trial Evaluating ProNAi's BCL2 Targeting DNAi(®) Therapeutic PNT2258 - VANCOUVER, BC and PLYMOUTH, MI, Jan.
Follicular lymphoma, a B cell lymphoma, is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide.
- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that
Walter and Eliza Hall Institute researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.
Pancreatic cancer is one of the most deadly and intractable forms of cancer, with a 5-year survival rate of only 6%.
Scientists from Melbourne, Australia recently discovered compounds known as BH3-mimetics currently being researched to treat leukemia may also be effective in treating breast cancer.
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.
- Growing in low tufty patches.